Archived content
DBR

Day1  |  Day 2 |  Short CoursesDownload Brochure

 


TUESDAY, NOVEMBER 3

12:30 pm Registration

TARGETING DIABETES AND OBESITY TOGETHER

2:00 Chairperson’s Opening Remarks

Reid Huber, Ph.D., Executive Director, Metabolic Endocrine Drug Development, Incyte Corporation

2:10 Modulating Lipid Metabolism

Cristina Rondinone, Ph.D., Director, Research, Metabolic Diseases, Roche Pharmaceuticals

2:40 FGF21 for Treatment of Metabolic Diseases

Jesper Gromada, Ph.D., Executive Director, Cardio-Vascular Metabolic Disease Area, Novartis Institutes for BioMedical Research

Fibroblast growth factor 21 (FGF21) is a potent metabolic regulator and a promising novel therapy for cardiovascular diseases, obesity and type 2 diabetes. In this talk I will review the preclinical pharmacology contributing to the actions of FGF21. A special emphasis will be placed on the molecular mechanisms by which FGF21 maintains energy homeostasis. In addition, knowledge gaps and challenges for further exploration of the therapeutic potential of this molecule will be addressed.

3:10 The Tipping Point between Life and Death of ER Stressed Pacreatic Beta Cells

Fumihiko Urano, M.D., Ph.D., Associate Professor of Molecular Medicine, University of Massachussetts Medical School

 

3:40 Networking Refreshment Break in the Exhibit Hall

4:20 Liver-directed Thyroid Beta Agonist for Targeting Cardio-metabolic Disease

Rebecca Taub, M.D., Senior Vice President, Research & Development, VIA Pharmaceuticals

VIA-3196, a liver-directed thyroid hormone beta agonist has the potential to provide benefit to patients with cardiometabolic risk including diabetics and dislipidemics. VIA-3196 lowers LDL cholesterol alone or in synergy with statins by greater than 40% in preclinical models, and reduces plasma triglicerides. VIA-3196 reduces hepatic triglicerides, a major cause of liver insulin resistance and non-alcoholic steatohepatitis. In animal models of diabetes and insulin reistance, VIA-3196 improves insulin sensitivity and lowers glucose to a similar level as rosiglitazone without causing weight gain.

4:50 Sponsored Presentation
(Sponsorship Opportunity Available)

5:20 Targeting the Gut for the Treatment of Metabolic Diseases

Andrew Swick, Ph.D., Senior Consultant, Illuminate BioPharma Consulting, LLC

5:50 Inhibiting Enterocytic MTP for Treatment of Diabetes and Metabolic Syndrome

Paul Sweetnam, Ph.D., Chief Scientific Officer, Surface Logix

SLx-4090 is a potent and selective small molecule inhibitor of microsomal triglyceride transfer protein (MTP). The compound was specifically designed to maximize therapeutic activity by targeting the enterocyte/intestinal wall while eliminating potential adverse effects associated with the inhibition of hepatic and/or cardiac MTP. Initial (2 week) clinical trials designed to explore the safety and effectiveness of this strategy indicated that SLx-4090 was well tolerated with no indication of LFT alterations. SLx-4090 was effective in reducing postprandial plasma triglycerides, chylomicrons and fasting LDL levels.    

6:20 Close of Day

Day1  |  Day 2 |  Short Courses 

 


Suggested Event Package (November 1 – 4):

November 1

Pre-Conference Short Courses:

Targeting GPCRs and Ion Channels with Antibodies (SC2)

November 2 - 3

Conference:

Ion Channels as Therapeutic Targets OR GPCR-Based Drug Discovery

November 3 - 4

Conference:

Targeting Diabetes with Novel Therapeutics

 

Arrow DownCONFERENCE-AT-A-GLANCE

Arrow DownDOWNLOAD 2015 BROCHURE

Arrow Overshort courses

Arrow OverVIEW ALL SPONSORS

Arrow OverVIEW MEDIA PARTNERS


SPONSORSHIPS & EXHIBITS

The exhibit hall was sold out in 2015, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2016, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com

 

DOT-Vid-recap

2015 Tracks

September 21

Next-Generation Histone Deacetylase Inhibitors Symposia

Strategies for Rare Diseases Symposia

September 22

Developing CRISPR-Based Therapies Symposia

September 22 - 23

Targeting Epigenetic Readers and Chromatin Remodelers

Targeting the Ubiquitin Proteasome System

Targeting the Microbiome

GPCR - Based Drug Discovery - Part 1

Antibodies Against Membrane Protein Targets - Part 1

RNAi for Functional Genomics Screening

Gene Therapy Breakthroughs

Targeting Ocular Disorders

September 23 - 24

Targeting Histone Methyltransferases and Demethylases

Targeting the Unfolded Protein Response

Kinase Inhibitor Discovery

GPCR-Based Drug Discovery - Part 2

Antibodies Against Membrane Protein Targets - Part 2

New Frontiers in Gene Editing

Quantitative Systems Pharmacology

2015 Short Courses

SC1: Cancer Metabolism: Pathways, Targets and Clinical Updates

SC2: Leveraging Data and Analytics for Drug DiSCovery

SC3: Setting Up Effective Rnai SCreens: From Design to Data to Validation

SC4: Phenotypic SCreening and Chemical Probe Development

SC5: GPCR Structure-based Drug Discovery

SC6: Targeting of GPCRs with Monoclonal Antibodies

SC7: Setting Up Effective Functional SCreens Using 3D Cell Cultures

SC8: Targeting Protein-protein Interactions: Biophysical Approaches

SC9: Preclinical Animal Models for Ocular Indications

SC10: Introduction to Allosteric Modulators and Biased Ligands of GPCRs

SC11: Introduction to Targeted Covalent Inhibitors

SC12: Assays and High-throughput SCreening for Novel Epigenetic Inhibitors

SC13: Gamification and Drug Target Challenges

SC14: A Primer to Gene Editing: Tools and Applications

SC15: Using Mechanistic Physiological Models In Drug Development